Steroid-free maintenance immunosuppression with sirolimus and low-dose cyclosporine in renal transplant recipients is associated with “excellent” long-term patient and graft survival and a low acute rejection rate, according to researchers.
Amer Rajab, MD, PhD, and collaborators at Ohio State University Medical Center studied 791 renal transplant recipients (731 first-transplant and 60 second-transplant patients) who were placed on the steroid-free regimen. Of these patients, 462 received living donor kidneys and 329 received deceased donor kidneys.
At the end of five years, about 85% of patients remained on the regimen and 15% were placed on chronic corticosteroid therapy, the researchers reported. The five-year patient and graft survival rates were 84.5% and 75.4%, respectively. The five-year death-censored graft survival rate was 92.3%.
Continue Reading
During the five-year follow-up, 103 patients died. Forty-two percent died from cardiovascular causes, 39% from sepsis, and 9% from malignancy.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.